Drug Database
Back to search

Netherlands· NL-2134ae652f51

Neparvis 24 mg/26 mg filmomhulde tabletten

A valsartan and sacubitril product containing sacubitril + sacubitril valsartan trinatriumhemipentahydraat + valsartan, registered in Netherlands by Novartis Europharm Limited. The same ATC class is registered in 15 of our 19 countries.

ATC C09DX04

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedNeparvis 24 mg/26 mg filmomhulde tabl…ATCC09DX04REGISTER NO.NL-2134ae652f51PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about sacubitril + sacubitril valsartan trinatriumhemipentahydraat + valsartanAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Valsartan and sacubitril is registered in 15 of 19 countries.

Countries holding a registration under ATC C09DX04 (valsartan and sacubitril), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose
Search valsartan and sacubitril products by name

Valsartan and sacubitril · ATC C09DX04

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
SACUBITRIL + SACUBITRIL VALSARTAN TRINATRIUMHEMIPENTAHYDRAAT + VALSARTAN
Manufacturer
Novartis Europharm Limited
Country
Netherlands (NL)
ATC code
C09DX04
ATC class
Valsartan and sacubitril
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/16/1103

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

8 interactions on record for valsartan and sacubitril.

Graded by severity as the source publishes them — 8 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check valsartan and sacubitril against other medicinesHow interaction checks work

Valsartan and sacubitril · interactions on record

8 records

  • 8 moderate

Most severe, free to view

  • NitisinoneA16AX04moderate
  • SimvastatinC10AA01moderate
  • RosuvastatinC10AA07moderate
  • Darunavir and cobicistatJ05AR14moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under C09DX04

Valsartan and sacubitril, as other registers publish it.

All valsartan and sacubitril products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a87bbd80-6bb8-4074-b333-0cc13e66c319
GET /v1/drugs/a87bbd80-6bb8-4074-b333-0cc13e66c319?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/neparvis-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Valsartan and sacubitril",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp118765",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSPOVIDON (E 1202)",
    "HYDROXYPROPYLCELLULOSE, LAAG GESUBSTITUEERD (E 463a)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "IJZEROXIDE ROOD  (E 172)",
    "IJZEROXIDE ZWART (E 172)",
    "MACROGOL 4000",
    "MAGNESIUMSTEARAAT (E 470b)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "SACUBITRIL",
    "SACUBITRIL VALSARTAN TRINATRIUMHEMIPENTAHYDRAAT",
    "VALSARTAN"
  ],
  "leaflet_url": null,
  "authorised_at": "2016/05/26",
  "procedure_number": "EMEA/H/C/004343",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/16/1103",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about valsartan and sacubitril.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console